The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the efficacy and safety of individualized treatment
of 6-mercaptopurine (6-MP) in Chinese children with acute lymphoblastic leukemia, and to
investigate the dose-concentration-response (DER) relationship between thiopurine metabolites
and adverse events. The individualized administration of 6-MP was established in Chinese
children with acute lymphoblastic leukemia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Wei Zhao
Collaborators:
Children's Hospital of Hebei Province Institute of Hematology & Blood Diseases Hospital Qianfoshan Hospital Qilu Hospital of Shandong University The Affiliated Hospital of Qingdao University